Clinical Trial

Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial

Study acronym: APOLLO-EU
Recruiting
View on ClinicalTrials.gov →
Summary
Evaluate the safety and efficacy of Medtronic Intrepid™ TMVR TF System in patients with moderate-to-severe or severe symptomatic mitral regurgitation, or moderate symptomatic mitral regurgitation combined with mitral stenosis in the presence of MAC who, by agreement of the local site multidisciplinary heart team experienced in mitral valve therapies, are unsuitable for treatment with approved transcatheter repair or surgical mitral valve intervention.
Protocol Amendment History 40 amendments
This ClinicalTrials.gov record has been amended 40 times since 2022-08-09; most recent amendment 2026-07-01.
Status change: Not Yet Recruiting → Recruiting 2023-01-24
Trial Details
NCT Number NCT05496998
Lead Sponsor Medtronic Cardiovascular
Conditions Mitral Regurgitation
Enrollment 400 participants
Start Date 2023-02-07
Primary Completion 2029-08 (estimated)
Study Completion 2038-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-06